Description_x000D_ General description_x000D_ Influenza virus hemagglutinin (HA) precursor is encoded by the gene mapped on segment 4. The encoded protein is a 76kDa surface glycoprotein and it exists as trimers on the envelope._x000D_ Immunogen_x000D_ Recombinant fragment corresponding to C-terminal region of Influenza A virus Hemagglutinin (HA) (A/WSN/1933(H1N1))._x000D_ Application_x000D_ Suggested starting dilutions are as follows: ICC/IF: 1:100-1:1000, WB: 1:500-1:3000. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user._x000D_ Physical form_x000D_ Phosphate-buffered saline, no preservative added._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ Influenza virus hemagglutinin (HA) acts as a key immunogen in avian influenza virus (AIV) vaccines. Activated HA facilitates virus attachment to oligosaccharide receptors on host cell surface and is involved in penetration through fusion following conformational modifications in the endolysosomal compartment. 226 and 228 residues in HA of the H3 subtype play a key role in host range restriction and receptor specificity._x000D_ Features and Benefits_x000D_ Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more._x000D_ Other Notes_x000D_ Purification: Affinity purified by Protein G